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S U M M A R Y
Objectives: The human leukocyte antigen (HLA) molecules have been shown to be important genetic
factors in several diseases. In this study we aimed to evaluate the possible role of HLA genes in the course
of Crimean-Congo hemorrhagic fever (CCHF) infection.
Methods: A total of 57 adult patients with CCHF and 43 healthy controls living in the same regions as the
patients were included in the study. Severe cases were deﬁned according to previously reported severity
criteria.
Results: The frequency of HLA-A*02 was found to be signiﬁcantly higher in the patients than in the
healthy controls (p = 0.021). However, a signiﬁcantly lower frequency of HLA-B*27 was observed in the
patients than in the healthy controls (p = 0.01). The relative risk (RR) of HLA-A*02 allele for CCHF was
found to be 1.93 (95% conﬁdence interval 1.11 < RR < 3.36). With regard to severe and non-severe cases,
there was a signiﬁcantly greater frequency of HLA-A*23 in severe cases (p = 0.014).
Conclusions: The results of this study indicate that while some HLA alleles could constitute a risk factor
for acquiring CCHF infection, others could have a protective role against the disease. This study also
presents the impact of genetic risk factors on the clinical course of the disease.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Environmental and host genetic factors affect host susceptibili-
ty to infections and other human diseases. The diversity of genes
involved in the immune response results in different immunologi-
cal reactions to infectious pathogens. Many genetic loci lead to
human disease susceptibility.1 A current area of interest in the
investigation of infectious diseases is genetic markers. The HLA
system, also known as major histocompatibility complex (MHC) in
humans, has been shown to be an important genetic factor in
several diseases, including infectious diseases, autoimmune
diseases, and cancer.1–3 This gene group is located on the short
arm of the sixth chromosome and exhibits extensive polymor-
phism. The HLA genes are divided into two functionally different
classes. Class I antigens (HLA-A, HLA-B, and HLA-C loci) are
expressed on somatic cells, and class II antigens (HLA-DR, HLA-DP,
and HLA-DQ loci) are expressed on immune cells, i.e. monocytes,
macrophages, dendritic cells, and T and B lymphocytes. The HLA
loci play a key role in the immune response to microorganisms and
susceptibility to several infectious diseases.1,2§ This study was presented at the EKMUD Congress, Istanbul, Turkey, March 1–5,
2011.
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http://dx.doi.org/10.1016/j.ijid.2013.06.005Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne viral
hemorrhagic disease with a mortality rate of 5–30%.4,5 The clinical
spectrum of this disease varies from a subclinical infection to
severe disease and death.6 No effective antiviral therapy is yet
available.7,8 This disease is an endemic zoonosis in Turkey,
appearing during the spring and summer seasons every year.4
Endemic areas are located in the Black Sea region, and the
dominant strains are the serotypes related to the strains from
southern Russia and the Balkan countries.4,9,10
The pathogenesis of CCHF is a complex process and has not been
described completely. Although endothelial damage and an
impaired immunological response to the virus are well deﬁned,
the relationship between host genetics and susceptibility to the
infection is not yet known.11,12 In this study we aimed to evaluate
the possible role of HLA genes in the susceptibility of the host to
CCHF infection and to investigate the effect of these molecules on
the severity of the disease.
2. Materials and methods
2.1. Patients and control group
This prospective case-controlled study was carried out during
the 2009–2010 seasons. A total of 57 adult patients hospitalized
with a diagnosis of CCHF were included in the study. The diagnosisses. Published by Elsevier Ltd. All rights reserved.
Table 1
The frequencies of HLA-A, HLA-B, HLA-Cw, HLA-DQB1, and HLA-DRB1 alleles in
patients and controls
HLA allele CCHF patients, n (%) Control group, n (%) p-Value
A*01 16 (14.0) 9 (10.5) NS
A*02 36 (31.6) 14 (16.3) 0.013a
A*03 13 (11.4) 12 (14.0) NS
A*11 8 (7.0) 12 (14.0) NS
A*23 4 (3.5) 5 (5.8) NS
A*24 17 (14.9) 15 (17.4) NS
A*26 6 (5.3) 5 (5.8) NS
A*29 - 4 (4.7) -
A*30 2 (1.8) 2 (2.3) NS
A*31 4 (3.5) - -
A*32 6 (5.3) 4 (4.7) NS
A*33 1 (0.9) - -
A*66 - 1 (1.2) -
A*68 1 (0.9) 2 (2.3) NS
A*69 - 1 (1.2) -
B*04 - 1 (1.2) -
B*07 10 (8.8) 4 (4.7) NS
B*08 2 (1.8) 4 (4.7) NS
B*13 3 (2.6) 2 (2.3) NS
B*14 1 (0.9) - -
B*15 5 (4.4) 2 (2.3) NS
B*18 5 (4.4) 6 (7.0) NS
B*27 2 (1.8) 9 (10.5) 0.007a
B*35 18 (15.8) 14 (16.3) NS
B*37 2 (1.8) 3 (3.5) NS
B*38 5 (4.4) 5 (5.8) NS
B*39 1 (0.9) - -
B*40 6 (5.3) 3 (3.5) NS
B*41 4 (3.5) 3 (3.5) NS
B*44 12 (10.5) 7 (8.1) NS
B*48 2 (1.8) 1 (1.2) NS
B*49 5 (4.4) 4 (4.7) NS
B*50 2 (1.8) - -
B*51 17 (14.9) 11 (12.8) NS
B*52 4 (3.5) 1 (1.2) NS
B*53 1 (0.9) - -
B*55 4 (3.5) 1 (1.2) NS
B*56 - 1 (1.2) -
B*57 2 (1.8) 2 (2.3) NS
B*58 - 1 (1.2) -
B*60 - 1 (1.2) -
B*78 1 (0.9) - -
Cw*01 4 (3.5) 3 (3.5) NS
Cw*02 7 (6.1) 8 (9.3) NS
Cw*03 8 (7.0) 6 (7.0) NS
Cw*04 19 (16.7) 21 (24.4) NS
Cw*05 3 (2.6) 3 (3.5) NS
Cw*06 11 (9.6) 6 (7.0) NS
Cw*07 19 (16.7) 15 (17.4) NS
Cw*08 3 (2.6) 1 (1.2) NS
Cw*12 15 (13.2) 9 (10.5) NS
Cw*14 9 (7.9) 3 (3.5) NS
Cw*15 8 (7.0) 7 (8.1) NS
Cw*16 6 (5.3) 3 (3.5) NS
Cw*17 2 (1.8) 1 (1.2) NS
DRB1*01 3 (2.6) - -
DRB1*03 9 (7.9) 6 (7.0) NS
DRB1*04 21 (18.4) 18 (20.9) NS
DRB1*07 8 (7.0) 11 (12.8) NS
DRB1*08 1 (0.9) 2 (2.3) NS
DRB1*09 3 (2.6) 1 (1.2) NS
DRB1*10 1 (0.9) - -
DRB1*11 25 (21.9) 25 (29.1) NS
DRB1*12 2 (1.8) 1 (1.2) NS
DRB1*13 16 (14.0) 7 (8.1) NS
DRB1*14 2 (1.8) 3 (3.5) NS
DRB1*15 16 (14.0) 9 (10.5) NS
DRB1*16 7 (6.1) 3 (3.5) NS
DQB1*02 16 (14) 15 (17.4) NS
DQB1*03 52 (45.6) 45 (52.3) NS
DQB1*04 1 (0.9) 3 (3.5) NS
DQB1*05 16 (14.0) 12 (14.0) NS
DQB1*06 29 (25.4) 11 (12.8) NS
NS, not signiﬁcant. Note: the sums of all alleles in CCHF patients and in the control
group were 114 and 86, respectively.
a Level of signiﬁcance <0.05 reached in comparisons: OR 0.421, 95% CI 0.210–
0.845; RR 1.93, 95% CI 1.11 < RR < 3.36, for HLA-A*02; OR 6.545, 95% CI 1.376–
31.130, for HLA-B*27.
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genome in patient serum samples. Molecular and serological
analyses were performed at the Virology Reference Laboratory of
the Reﬁk Saydam National Public Health Agency (Ankara, Turkey).
The TaqMan-based one-step reverse-transcriptase PCR assay (RT-
PCR) was used to detect CCHF viral RNA.13 The presence of CCHF-
speciﬁc serum IgM antibodies was determined by in-house ELISA
method. The antigens used in the ELISA tests were obtained from
the Centers for Disease Control and Prevention (CDC, Atlanta, GA,
USA). Patient demographic, clinical, and laboratory data were
recorded on individual forms. The control group (n = 43) was
chosen from healthy solid organ donors who presented to the
Organ Transplantation Center and who were living in the same
regions as the CCHF patients. Ethics committee approval for
genetic studies was obtained. All patients and control group
members provided informed consent for participation in a genetic
study.
2.2. HLA typing
HLA typing for A, B, Cw, DQB, and DRB loci was done using a
medium-resolution PCR sequence-speciﬁc oligonucleotide (PCR-
SSO) technique. For this purpose, LIFECODES HLA SSO typing kits
were provided by Gen-Probe Transplant Diagnostics (Gen-Probe
Transplant Diagnostics, Inc., Stamford, CT, USA). When the typing
results indicated more than two possible alleles, high-resolution
PCR kits with sequence-speciﬁc primers (PCR-SSP; Olerup SSP AB,
Saltsjo¨baden, Sweden) were used to resolve ambiguities. The
frequencies of HLA alleles, haplotypes, and genotypes were
determined for all of the patients and control group.
2.3. Deﬁnition of severe cases
Previously reported disease severity criteria were used to deﬁne
the severe cases.14 Patients with at least one of the following were
considered as severe cases: somnolence, melena, activated partial
thromboplastin time (APTT) 60 s, and thrombocyte count
20  109/l. Fatal cases were also included in the severe group.
2.4. Statistical analysis
The frequencies of HLA alleles were compared between the
patients and control group and between the non-severe and severe
cases. Statistical analyses were performed using SPSS 15.0
statistical package (SPSS Inc., Chicago, IL, USA). Variables were
compared by Chi-square test and Fisher’s exact test with Yates’
correction. The level of signiﬁcance was set at a p-value of <0.05.
3. Results
The study was performed on 57 adult CCHF patients (31 male,
26 female) and 43 healthy controls (22 male, 21 female). There was
no signiﬁcant difference in the area of residence between the
patients and controls (p = 0.283). In the patient group, HLA-A*02,
HLA-B*35, HLA-Cw*04, HLA-DRB1*11, and HLA-DQB1*03 had the
highest frequencies in their own HLA loci (Table 1). When
comparing the frequencies of HLA alleles between the patients
and the control group, the frequency of HLA-A*02 was found to be
signiﬁcantly higher in the patients than in the healthy controls
(p = 0.021). On the other hand, a signiﬁcantly lower frequency of
HLA-B*27 was observed in the patients than in the healthy controls
(p = 0.01).
According to the categorization of the patients by severity
criteria, 20 patients were assigned to the severe group and 37
patients were assigned to the non-severe group. Eleven patients in
the severe group had a fatal outcome. In the severe and non-severe
Table 2
The frequencies of HLA-A, HLA-B, HLA-Cw, HLA-DQB1, and HLA-DRB1 alleles in
non-severe and severe cases
HLA alleles Non-severe group, n (%) Severe group, n (%) p-Value
A*01 11 (14.9) 5 (12.5) NS
A*02 22 (29.7) 14 (35.0) NS
A*03 9 (12.2) 4 (10.0) NS
A*11 7 (9.5) 1 (2.5) NS
A*23 0 (0) 4 (10.0) 0.014a
A*24 12 (16.2) 5 (12.5) NS
A*26 3 (4.1) 3 (7.5) NS
A*30 2 (2.7) - -
A*31 4 (5.4) - -
A*32 4 (5.4) 2 (5.0) NS
A*33 - 1 (2.5) -
A*68 - 1 (2.5) -
B*07 8 (10.8) 2 (5.0) NS
B*08 2 (2.7) - -
B*13 3 (4.1) - -
B*14 - 1 (2.5) -
B*15 5 (6.8) - -
B*18 2 (2.7) 3 (7.5) NS
B*27 1 (1.4) 1 (2.5) NS
B*35 13 (17.6) 5 (12.5) NS
B*37 1 (1.4) 1 (2.5) NS
B*38 1 (1.4) 4 (10.0) NS
B*39 - 1 (2.5) -
B*40 4 (5.4) 2 (5.0) NS
B*41 2 (2.7) 2 (5.0) NS
B*44 7 (9.5) 5 (12.5) NS
B*48 2 (2.7) - -
B*49 2 (2.7) 3 (7.5) NS
B*50 1 (1.4) 1 (2.5) NS
B*51 11 (14.9) 6 (15.0) NS
B*52 3 (4.1) 1 (2.5) NS
B*53 1 (1.4) - -
B*55 2 (2.7) 2 (5.0) NS
B*57 2 (2.7) - -
B*78 1 (1.4) - -
Cw*01 2 (2.7) 2 (5.0) NS
Cw*02 4 (5.4) 3 (7.5) NS
Cw*03 4 (5.4) 4 (10.0) NS
Cw*04 14 (18.9) 5 (12.5) NS
Cw*05 2 (2.7) 1 (2.5) NS
Cw*06 8 (10.8) 3 (7.5) NS
Cw*07 13 (17.6) 6 (15.0) NS
Cw*08 2 (2.7) 1 (2.5) NS
Cw*12 6 (8.1) 9 (22.5) NS
Cw*14 7 (9.5) 2 (5.0) NS
Cw*15 6 (8.1) 2 (5.0) NS
Cw*16 5 (6.8) 1 (2.5) NS
Cw*17 1 (1.4) 1 (2.5) NS
DRB1*01 3 (4.1) - -
DRB1*03 5 (6.8) 4 (10.0) NS
DRB1*04 15 (20.3) 6 (15) NS
DRB1*07 5 (6.8) 3 (7.5) NS
DRB1*08 1 (1.4) - -
DRB1*09 2 (2.7) 1 (2.5) NS
DRB1*10 - 1 (2.5) -
DRB1*11 14 (18.9) 11 (27.5) NS
DRB1*12 2 (2.7) - -
DRB1*13 8 (10.8) 8 (20.0) NS
DRB1*14 1 (1.4) 1 (2.5) NS
DRB1*15 13 (17.6) 3 (7.5) NS
DRB1*16 5 (6.8) 2 (5.0) NS
DQB1*02 9 (12.2) 7 (17.5) NS
DQB1*03 36 (48.6) 16 (40.0) NS
DQB1*04 1 (1.4) - -
DQB1*05 11 (14.9) 5 (12.5) NS
DQB1*06 17 (23.0) 12 (30.0) NS
NS, not signiﬁcant. Note: the sums of all alleles in the non-severe group and in the
severe group were 74 and 40, respectively.
a Level of signiﬁcance <0.05 reached in comparisons: OR 0.327, 95% CI 0.250–
0.428, for HLA-A*23.
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frequent HLA alleles in HLA-A and HLA-DQB1 loci. For the other loci
(HLA-DRB1, HLA-B, HLA-Cw), while HLA-DR1*04, HLA-B*35, and
HLA-Cw*04 had the highest frequencies in their own loci in non-
severe cases, HLA-DR1*11, HLA-B*51, and HLA-Cw*12 had the
highest frequencies in the severe group (Table 2). The greater
frequency of HLA-A*23 in severe cases was the only statistically
signiﬁcant difference between the two groups.
4. Discussion
An effective host immune response plays an important role in
the response to infection. Genetic factors affect the functions of
immune cells and ﬁnally the outcome of the infection. The
association of HLA molecules with infections allows investigations
to deﬁne the alleles affecting the susceptibility to infection or
protection from infection in different ethnic groups, and to
determine the genetic predisposition to speciﬁc infectious
diseases, deﬁning the population at risk.1,2 Genetic studies may
also provide the molecular basis for vaccine development studies.
The mechanism of action of HLA genes on the immune response
against viral particles and the production of neutralization
antibodies provide an insight into the presentation of safe and
efﬁcient new viral vaccines.1
Several studies have sought to determine the association
between bacterial, parasitic, and viral infectious diseases and HLA
molecules. For instance, a relationship was demonstrated between
the HLA-DR2 molecule and susceptibility to pulmonary tubercu-
losis.15 The frequency of the HLA-DRB1 allele was found to be
signiﬁcantly higher in lepromatous leprosy patients than in
tuberculoid leprosy patients.16 In endemic regions, a protective
role of the HLA molecules against malaria by control of the immune
response has been well established. Investigations suggest that the
relationship between HLA-B53 alleles and protection from severe
malaria results from restriction of cytotoxic T lymphocytes during
the liver stage of the parasite.17,18 The risk of kala-azar has been
found to be higher in those persons positive for the HLA-A26
allele.19
In viral infections, the HLA-restricted cytotoxic T-lymphocyte
(CTL) response plays a major role in the host immune response
against the viruses.1 In particular, class I HLA molecules are very
important for the lysis of infected cells by CTLs. An association
between the HLA molecules and susceptibility or resistance to
various viral infections has been found in several infections.1,2
There are numerous studies reporting the effect of the HLA
molecules on the course of viral infections including HIV infection,
dengue hemorrhagic fever, hantavirus infection, hepatitis B,
hepatitis C, and Epstein–Barr virus infection.20–25 However we
could not ﬁnd any study investigating the relationship between
CCHF and HLA molecules. Several studies on hantavirus, which
belongs to the same family (Bunyaviridae) as CCHF virus, have
shown that the outcome of hemorrhagic fever with renal syndrome
(HFRS) is determined by an interaction between the virus,
immunological factors, and human genetics. A relationship
between HLA alleles and the clinical course of the disease was
established.26,27 Different associations of HLA molecules with
different virus types have also been determined. The frequency of
HLA-B*35 was found to be signiﬁcantly higher in Dobrova virus-
infected patients, while HLA-DRB1*13 was found to be signiﬁcant-
ly higher in Puumala virus infections. These HLA alleles were also
found to be signiﬁcantly higher in the severe form of the disease.
However, HLA-B*07 allele was found to be more frequent in
patients with mild disease and associated with a protective role
against severe HFRS caused by Puumala virus.25
The CCHF virus causes a delay in the adaptive immune
response, which is critical for clearance of the virus.28–30 The
E. Akıncı et al. / International Journal of Infectious Diseases 17 (2013) e1038–e1041 e1041adaptive immune response in humans involves the HLA system,
which takes place in the presentation of pathogen-derived
peptides to the T-cells and subsequently initiation of the adaptive
immune response.25 The severity of CCHF infection varies between
patients. Some predictors of mortality have been deﬁned in several
clinical investigations.14,31–34 These predictors are based on
laboratory and clinical data. However there is no publication
identifying the genetic predisposition toward the clinical course of
the infection. In this study, the HLA-A*02 allele was more frequent
in the patient group than in the healthy controls. Therefore, HLA-
A*02 might be associated with susceptibility to the disease. On the
other hand, HLA-B*27 might have a protective role in CCHF, since
the frequency of HLA-B*27 was signiﬁcantly lower in patients than
in controls. A signiﬁcant correlation between HLA-A*23 and severe
CCHF cases was also detected, indicating that HLA-A*23 might be a
genetic risk factor for progression to severe CCHF.
In conclusion, this study indicates that while some HLA alleles
could constitute a risk factor for severe CCHF infection, others
could have a protective role against the severe form of the disease.
Of importance, this study presents the impact of genetic factors on
the clinical course of the disease and will encourage further genetic
studies in endemic populations. However, there are some
limitations to this study. The number of patients was limited
and only some HLA regions were investigated as genetic markers.
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